Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03821324
Other study ID # VI1118
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 11, 2018
Est. completion date October 3, 2019

Study information

Verified date March 2021
Source Venus Concept
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, single centre, evaluator-blind study of the safety and performance of fractional radiofrequency (RF) for the treatment and reduction of acne scarring. The study will evaluate the progress of 15 subjects requesting treatment of acne scarring. The study will involve three treatments on both sides of the face with 3-5 week intervals between each treatment. Subjects will be followed at 6 and 12 weeks after their last treatment. Analysis will be performed on all subjects who receive at least one treatment.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date October 3, 2019
Est. primary completion date October 3, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria: 1. Healthy, male or female subjects over 21 years of age who are seeking treatment and reduction of their acne scarring. 2. Able to read, understand and voluntarily provide written Informed Consent. 3. Able and willing to comply with the treatment/follow-up schedule and requirements. 4. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study and have a negative Urine Pregnancy test at baseline. Exclusion Criteria: 1. Implantable defibrillators, cardiac pacemakers, and other metal implants 2. Subjects with any implantable metal device in the treatment area 3. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant). 4. Permanent implant in the treated area, such as metal plates and screws, or an injected chemical substance. 5. Current or history of any kind of cancer, or pre-malignant moles. 6. Severe concurrent conditions, such as cardiac disorders. 7. Pregnancy or intending to become pregnant during the study and nursing. 8. Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications. 9. History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only after a prophylactic regime has been followed for 2 weeks or longer prior to enrollment, or according to Investigator's discretion. 10. Poorly controlled endocrine disorders, such as diabetes. 11. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash. 12. History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin. 13. History of bleeding coagulopathies, or use of anticoagulants (excluding daily aspirin). 14. Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last three months, if face is treated. 15. Use of isotretinoin (Accutane®) or other systemic retinoids within six months or topical retinoids within three months prior to treatment; or as per physician's discretion. 16. Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g. ibuprofen-containing agents) one week before and after each treatment session. 17. Any surgical procedure in the treatment area within the last six months or before complete healing. 18. Treating over tattoo or permanent makeup. 19. Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks. 20. As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Venus Viva
The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.

Locations

Country Name City State
United States Sadick Research Group New York New York

Sponsors (1)

Lead Sponsor Collaborator
Venus Concept

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acne Scar Improvement Change in acne scarring at 12 weeks post-treatment compared to baseline as assessed by blinded evaluators using photographs a 7-point Global Aesthetic Improvement Scale (GAIS) (ranges from -3 Very Much Worse to +3 Very Much Improved). 12 weeks post-final treatment (approximately Week 20)
Secondary Subject Satisfaction Subjects' assessment of satisfaction with the treatment using a 5-point Subject Satisfaction Scale (ranging from 0 Very Unsatisfied to 4 Very Satisfied) at 6 weeks and 12 weeks post-treatment. 12 weeks post-final treatment (approximately Week 20)
Secondary Subject Scale - Visual Analog Scale for Pain Subjects' assessment of discomfort and pain after treatments as measured by a 10 cm visual analog scale (VAS) with 0 being no pain and 10 being pain as bad as it can be. Each subject was asked to rate their pain after each of the 3 treatments. The result is the mean of each subject's mean VAS score. Immediately post-treatment at each treatment (average of all 3 treatments)
Secondary Treatment Tolerability Subjects' assessment of treatment tolerability as measured by a 5-point scale ranging from 0 (Very Intolerable) to 4 (Very Tolerable). Immediately post-treatment at each treatment (mean of the tolerability scores following each of the 3 treatments)
See also
  Status Clinical Trial Phase
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Active, not recruiting NCT01696513 - Effect of Subcision and Suction on Acne Scars N/A
Completed NCT01115634 - Autologous Fibroblast Transplantation in Facial Deformities Phase 2
Completed NCT05254210 - Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device N/A
Completed NCT05102617 - Post Market Usability Evaluation Of The PicoSure Pro Device N/A
Completed NCT02103816 - The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars N/A
Completed NCT01221922 - Laser Treatment of Acne Scars in Fitzpatrick Skin Types III-VI N/A
Completed NCT03767153 - Clinical Evaluation of Fractional Radiofrequency for the Treatment of Acne Scarring N/A
Completed NCT00974870 - A Pilot Study Testing the Efficacy of a Needling Device for the Treatment of Acne Scars N/A
Not yet recruiting NCT05579171 - Lasers to Aid in Treatment of Acne Scars N/A
Not yet recruiting NCT02126657 - The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Acne Scars Phase 2
Completed NCT02145364 - Ultherapy® for the Treatment of Acne Scars N/A
Enrolling by invitation NCT01847066 - Epidermal Delivery of Ani-Aging Ingredients N/A
Recruiting NCT03850925 - Comparison of Picosecond Pulsed Nd:YAG Laser and Fractional Laser for the Treatment of Acne Scars N/A
Active, not recruiting NCT04807179 - Clinical Study to Evaluate Alexandrite Laser for the Treatment of Acne Scars N/A
Terminated NCT02955381 - Restylane Silk Acne Scar Efficacy Evaluation Study N/A
Completed NCT01213199 - Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars Phase 2
Completed NCT03380845 - Comparison of 1,550-nm Laser and Fractional Radiofrequency Microneedle for the Treatment of Acne Scars in Ethnic Skin N/A
Active, not recruiting NCT03901417 - Comparison of 1550nm Fractional Laser Alone Versus in Combination With Microneedling for the Treatment of Acne Scars N/A
Completed NCT03522922 - Efficacy of Microneedling With Topical Vitamin C in Treatment of Acne Scarring Phase 1/Phase 2